Denmark: Zealand Pharma A/S, a biotechnology company focused on the discovery and development of peptide-based medicines, has announced that all closing conditions in the collaboration and license agreement with Roche announced on March 12, 2025 have been satisfied, including regulatory conditions, and the agreement has become effective.“We are incredibly excited to launch this partnership, which represents a step change to realize Zealand Pharma’s vision of becoming a key player in the future management of obesity. Roche ticked all the right boxes for what we were looking for in a partner and we look very much forward to working closely together to unlock the full potential of petrelintide to benefit people who are overweight or obese”, said Adam Steensberg, Chief Executive Officer at Zealand Pharma. Read also: EMA Committee recommends EU label update for Roche Phesgo to allow administration outside of clinical settingsMore than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development partnerships with a number of pharma companies as well as commercial partnerships for its marketed products.Zealand was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the United States. Read also: Roche secures USFDA Breakthrough Device Designation for AI-driven companion diagnostic for non small cell lung cancer